Cogent Biosciences, Inc. (COGT)
38.12
+1.06
(+2.87%)
USD |
NASDAQ |
Feb 24, 09:47
Cogent Biosciences Research and Development Expense (Quarterly) : 74.38M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Merck & Co., Inc. | 3.992B |
| Sarepta Therapeutics, Inc. | 218.89M |
| Cidara Therapeutics, Inc. | 35.53M |
| BridgeBio Pharma, Inc. | 112.87M |
| Olema Pharmaceuticals, Inc. | 39.95M |